Dragonfly Therapeutics to Present Preclinical Data on Clinical-Stage DF6215, its Engineered IL-2R alpha-active Agonist, and DF9001, its EGFR-targeting TriNKET®, at the Society for Immunotherapy of Cancer Annual Conference

Dragonfly Therapeutics, Inc. Massachusetts

View original content:https://www.prnewswire.co.uk/news-releases/dragonfly-therapeutics-to-present-preclinical-data-on-clinical-stage-df6215-its-engineered-il-2r-alpha-active-agonist-and-df9001-its-egfr-targeting-trinket-at-the-society-for-immunotherapy-of-cancer-sitc-annual-conference-302299009.html